icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetics of Selonsertib, GS-9674,
and/or GS-0976 in Combination in Healthy Subjects

 
 
  Reported by Jules Levin
EASL 2017
 
International Liver Congress™, 19-23 April 2017, Amsterdam, the Netherlands
 
Cara H. Nelson, Brian J. Kirby, Na Lu, Bryan McColgan, C. Stephen Djedjos, Robert P. Myers, Jennifer Cuvin, Ann Qin, Anita Mathias
Gilead Sciences, Inc., Foster City, California, USA
 
Evaluation of the Safety and Pharmacokinetics of the Oral, Nonsteroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers - (11/29/16)
 
FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH - (12/02/16)
 
GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial - (11/21/16)
 
Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) - (10/21/16)
 

0523171

0523172

0523173

0523174

0523175

References
 
1. Loomba R, et al. AASLD 2016, abstr LB-3; 2. Djedjos CS, et al. AASLD 2016, poster 1077;
3. Westlin WF. EASL 2016, oral PS108; 4. Nelson CH, et al. EASL 2017, poster THU-343